Human endogenous retroviruses (HERVs) are endogenous viral elements in the genome that closely resemble and can be derived from retroviruses. They comprise up to 8% of the human genome. HERV-K is the most active ERV family in human genome. It is demonstrated that type 1 HERV-K envelope (env) transcripts are expressed in most human breast cancers, but not in normal breast tissues.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Receptor Construction||Vector Type||Targeting Cell Type||Inquiry & Datasheet|
|CAR-LC051||Anti-HERV-K env (6H5) h(CD28-CD3ζ) CAR, pCDCAR1||HERV-K||6H5||Mouse||scFv-CD28-CD3ζ||Lentiviral||T cell|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases||Inquiry & Datasheet|
|VP-CAR-LC542||Lenti-HERV-K env CAR (scFv-CD28-CD3ζ, 6H5) Viral Particle||6H5||EF1a||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE